Provention Bio, Inc. (PRVB)

NASDAQ: PRVB · IEX Real-Time Price · USD
4.67
+0.26 (5.90%)
Aug 8, 2022 4:00 PM EDT - Market closed
5.90%
Market Cap 380.84M
Revenue (ttm) 2.72M
Net Income (ttm) -104.51M
Shares Out 81.55M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 740,315
Open 4.53
Previous Close 4.41
Day's Range 4.50 - 4.71
52-Week Range 3.19 - 8.04
Beta 2.44
Analysts Buy
Price Target 16.75 (+258.7%)
Earnings Date Aug 4, 2022

About PRVB

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; ... [Read more...]

Industry Pharmaceuticals
CEO Ashleigh Palmer
Employees 82
Stock Exchange NASDAQ
Ticker Symbol PRVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PRVB stock is "Buy." The 12-month stock price forecast is 16.75, which is an increase of 258.67% from the latest price.

Price Target
$16.75
(258.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022- -Company completes $60.0 million private placement- RED BANK, N.J. , Aug. 4, 2022 /PRNewswire/ -- Proven...

Provention Bio Announces the Grant of Inducement Awards

RED BANK, N.J. , Aug. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today an...

Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it ...

This Stock Could Soar by Nearly 300%, Says Wall Street

Are the Street's predictions too optimistic?

Provention Bio Announces $60 Million Private Placement

RED BANK, N.J. , July 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today an...

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

RED BANK, N.J. , June 30, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today a...

Provention Bio to Present at the Jefferies Global Healthcare Conference

RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that mana...

Provention Bio Announces Update to Board of Directors

RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffr...

2 High-Risk, High-Reward Stocks for Contrarian Investors

Feeling adventurous?

Other symbols: BLUE

Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab...

RED BANK, N.J. , May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today an...

Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update

-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022- -Company to host teplizumab commercial launch investor event on Th...

Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022

RED BANK, N.J. , April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it...

Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months

Provention Bio Inc (NASDAQ: PRVB) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention ...

Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers RED BANK, N.J. , March 28, 2022 /PRNewswire/ --...

Provention Bio to Present at Two Upcoming Virtual Investor Conferences

RED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that mana...

Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

RED BANK, N.J., Feb. 24, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial ...

Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response...

RED BANK, N.J., Feb. 22, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today an...

Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

RED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it w...

Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference

RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that mana...

Provention Bio Announces the Grant of Inducement Award

RED BANK, N.J., Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ann...

Why Provention Bio Stock Skyrocketed Today

The momentum from the company's good news last week is continuing this week.

Why Provention Bio Stock Is Soaring Today

The company plans to refile for approval of its experimental type 1 diabetes therapy.